Cell targeting by murine retroviral vectors

Critical Reviews in Oncology/Hematology

Volumn 28, Issue 1, 1998, Pages 7-30

  Karavanas, Georgios ^a,b   Marin, Mariana ^a   Salmons, Brian ^c   Günzburg, Walter H ^d   Piechaczyk, Marc ^a  

^a CNRS   (France)

^b UNIVERSITY OF PATRAS   (Greece)

^c Bavarian Nordic GmbH   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

EXPRESSION VECTOR; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENE TECHNOLOGY; HUMAN; NONHUMAN; PROMOTER REGION; RETROVIRUS; REVIEW;

EID: 0032102415     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00007-9     Document Type: Article

References (203)

1. [1] Kay M, Woo S. Gene therapy for metabolic disorders. Trends Genet 1994;10:253-7.
2. [2] Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995;270:404-10.
3. [3] Anderson W. Human gene therapy. Science 1992;256:808-13.
4. [4] Mulligan R. The basic science of gene therapy. Science 1993;260:926-32.
5. [5] Günzburg W, Salmons B. Virus vector design in gene therapy. Mol Med Today 1995;2:410-7.
6. [6] Vile R, Russell SJ. Gene transfer technologies for the gene therapy of cancer. Gene Ther 1994;1:88-98.
7. [7] Vile R, Russell S. Retroviruses as vectors. Br Med Bull 1995;51:12-30.
8. [8] Marin M, Noël D, Piechaczyk M. Towards efficient cell targeting by recombinant retroviruses. Mol Med Today 1997;3:396-403.
9. [9] Coffin JM. Retroviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Raven, 1996:1767-847.
10. [10] Hunter E, Swanstrom R. Retrovirus envelope glycoproteins. Curr Top Microbiol Immunol 1990;157:187-253.
11. [11] Weiss R. Cellular receptors and viral glycoproteins involved in retrovirus entry. In: Levy JA, editor. The Retroviridae. New York: Plenum Press, 1993:1-108.
12. [12] Schulz TF, Jameson BA, Lopalco L, Siccardi AG, Weiss RA, Moore J. Conserved structural features in the interaction between retroviral surface and transmembrane glycoproteins. AIDS Res Hum Retrov 1992;8:1571-80.
13. [13] Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995;2:1075-82.
14. [14] Tucker SP, Srinivas RV, Compans RW. Molecular domains involved in oligomerization of the Friend murine leukemia virus envelope glycoprotein. Virology 1991;185:710-20.
15. [15] Li X, McDermott B, Yuan B, Goff SP. Homodimeric interactions between transmembrane proteins of Moloney murine leulemia virus. J Virol 1996;70:1266-70.
16. [16] Rein A, Mirro J, Haynes J, Ernest S, Nagashima K. Function of the cytoplasmic domain of a retroviral transmembrane protein: p15E-p2E cleavage activates the membrane fusion capability of the murine leukemia virus Env protein. J Virol 1994;68:1773-81.
17. [17] Ragheb JA, Anderson WF. pH-independent murine leukemia virus ecotropic envelope-mediated cell fusion: implications for the role of the R peptide and p12E TM in viral entry. J Virol 1994;68:3220-31.
18. [18] Januszeski M, Cannon PM, Cheng D, Rosenberg Y, Anderson WF. Functional analysis of the cytoplasmic tail of Moloney murine leukemia virus envelope protein. J Virol 1997;71:3613-9.
19. [19] Yang C, Compans RW. Analysis of the cell fusion activities of chimeric simian immunodeficiency virus-murine leukemia virus envelope proteins: inhibitory effects of the R peptide. J Virol 1996;70:248-54.
20. [20] Bae Y, Kingman SM, Kingsman AJ. Functional dissection of the Moloney murine leukemia virus envelope protein gp70. J Virol 1997;71:2092-9.
21. [21] Zhao Y, Lee S, Anderson F. Functional interactions between monomers of the retroviral envelope protein complex. J Virol 1997;71:6967-72.
22. [22] Heard JM, Danos O. An amino-terminal fragment of Friend murine luekemia virus envelope glycoprotein binds the ecotropic receptor. J Virol 1991;65:4026-32.
23. [23] Yu H, Soong NW, Anderson WF. Binding kinetics of ecotropic (Moloney) murine leukemia retrovirus with NIH 3T3 cells. J Virol 1995;69:6557-62.
24. [24] Mackrell AJ, Soong NW, Curtis CM, Anderson WF. Identification of a subdomain in the Moloney murine leukemia virus envelope protein involved in receptor binding. J Virol 1996;70:1768-74.
25. [25] Battini J, Danos O, Heard J. Receptor-binding domain of murine leukemia virus envelope glycoproteins. J Virol 1995;69:713-9.
26. [26] Battini JL, Heard JM, Danos O. Receptor choice determinants in the envelope glycoproteins of amphotropic, xenotropic and polytropic murine leukemia viruses. J Virol 1992;66:1468-75.
27. [27] Battini JL, Kayman SC, Pinter A, Heard JM, Danos O. Role of N-linked glycosylation in the activity of the Friend murine leukemia virus SU protein receptor-binding domain. Virology 1994;202:496-9.
28. [28] Miller AD. Cell-surface receptor for retroviruses and implications for gene transfer. Proc Natl Acad Sci USA 1996;93:11407-13.
29. [29] Weiss R, Tailor C. Retrovirus receptors. Cell 1995;82:531-3.
30. [30] Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS virus. Nature 1984;312:763-7.
31. [31] Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behave as the receptor for human LAV. Nature 1984;312:767-8.
32. [32] Albritton LM, Tseng L, Scadden D, Cunningham JM. A putative murine ecotropic receptor gene encodes a multiple-spanning protein and confers susceptibility to infection. Cell 1989;57:659-66.
33. [33] Wang H, Kavanaugh MP, North RA, Kabbat D. Nature 1991;352:729-31.
34. [34] Kim JW, Closs EI, Albritton LM, Cunningham JM. Nature 1991;352:725-8.
35. [35] O'Hara B, Johann S, Klinger H, et al. Characterization of the human gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell Growth Diff 1990;1:119-27.
36. [36] Kavanaugh MP, Miller DG, Zhang W, Law W, Kozak SL, Kabat D, Miller AD. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci USA 1994;91:7071-5.
37. [37] Takeuchi Y, Vile RG, Simpson G, O'Hara B, Collins MK, Weiss RA. Feline leukemia virus subgroup B Uses the same cell surface receptor as gibbon ape leukemia virus. J Virol 1992;66:1219-22.
38. [38] vanZeijl M, Johann SV, Closs E, Cunnigham J, Eddy R, Shows TB, O'Hara B. Proc Natl Acad Sci USA 1994;91:1168-72.
39. [39] Miller D, Edwards R, Miller A. Cloning of the cellular receptors for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc Natl Acad Sci USA 1994;91:78-82.
40. [40] Bates P, Young JA, Varmus HE. Cell 1993;74:1043-51.
41. [41] Brojatsch J, Naughton J, Rolls MM, Zingler K, Young JAT. CAR1, a TNF-related protein, is a cellular receptor for cytopathic avian leukosis-sarcoma viruses and mediates apoptosis. Cell 1996;87:845-55.
42. [42] Ban J, Porteteile D, Altaner C, et al. J Virol 1993;67:1050-7.
43. [43] Willett BJ, Hosie MJ, Jarett O, Neil JC. Immunology 1994;81:228-33.
44. [44] Hosie MJ, Willett BJ, Dunsford TH, Jarrett O, Neil JC. J Virol 1993;67:1667-71.
45. [45] Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg DH, Gonzales-Scarano F. Inhibitionof entry of HIV-1 into neural cell lines by antibodies against galactosyl ceramide. Science 1991;253:320-2.
46. [46] Harouse JM, Kunsch C, Hartle HT, Laughlin MA, Hoxie JA, Wigdahl B, Gonzales-Scarano F. CD4-independent infection of human neural cells by human immunodeficiency virus type 1. J Virol 1989;63:2527-35.
47. [47] Williams AF. Cellular interactions out of equilibrium. Nature 1991;352:473-4.
48. [48] Lawrence MB, Kennan WS, Gould MN, Bremel RD. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 1991;65:859-73.
49. [49] Chen Y, et al. Dengue virus infectivity depends on envelope protein binding to target heparan sulfate. Nat Med 1997;3:866-71.
50. [50] Jackson T, Ellard FM, Ghazaleh RA, et al. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 1996;70:5282-7.
51. [51] Ohshiro Y, Murakami T, Matsuda K, Nishioka K, Yoshida K, Yamamoto N. Role of cell surface glycoaminoglycans of human T cells in human immunodeficiency virus type-1 infection. Microbiol Immunol 1996;40:827-35.
52. [52] Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski H, Norcross MA. Medaition of humanb immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. J Virol 1995;69:2233-9.
53. [53] Patel M, Yanagishita M, Roderiquez G, Bou-Habib DC, Oravecz T, Hascall VC, Norcross MA. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res Hum Retrovir 1993;9:167-74.
54. [54] Clapham PR, Weiss RA. Spoilt for choice of co-receptors. Nature 1997;388:230-1.
55. [55] D'Souza MP, Harden VA. Chemokines and HIV-1 second receptors. Nat Med 1996;2:1293-300.
56. [56] Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-62.
57. [57] Willett BJ, Picard L, Hosie MJ, Turner JD, Adema K, Clapham PR. Shared usage of the chemokine receptor CXCR4 by the Feline and Human immunodeficiency viruses. J Virol 1997;71:6407-15.
58. [58] Wild C, Dubay JW, Greenwell T, et al. Propensity for a leucinezipper-like domain of a human immunodeficiency virus typel gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 1994;91:12676-80.
59. [59] Harter C, Bachi T, Semenza G, Brunner J. Hydrophobic photo-labeling identifies BHA2 as the subunit mediating the bromelain-solubilized influenza hemagglutinin with liposomes at low pH. Biochemistry 1988;27:1856-64.
60. [60] Stegman T, Nir S, Wilschut J. Membrane fusion activity of influenza virus. Effects of gangliosides and negatively charged phospholipids in target liposomes. Biochemistry 1989;28:1698-704.
61. [61] Andersen KB, Nexo BA. Entry of murine retroviruses into mouse fibroblasts. Virology 1983;125:85-98.
62. [62] McClure M, Sommerfeit M, Marsh M, Weiss R. The pH independence of mammalian retrovirus infection. J Gen Virol 1990;71:767-73.
63. [63] McClure MO, Marsh M, Weiss RA. Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J 1988;7:513-8.
64. [64] Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997;71:5871-7.
65. [65] Timar J, Nagy K, Robertson D, Clapham P, Weiss RA. Ultrastructure and immunoelectron microscopy of human T-cell leukaemia virus-type I producing lymphoid human tumour cells. J Gen Virol 1987;68:1011-20.
66. [66] Clapham P, Nagy K, Cheingsong-Popov R, Exley M, Weiss RA. Productive infection and cell-free transmission of human T-cell leukemia virus in a non-lympoid cell line. Science 1983;222:1125-7.
67. [67] Moore JP, Keating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990;250:1139-42.
68. [68] Allan J, Strauss S, Buck DW. Enhancement of SIV by soluble receptor molecules. Science 1990;247:1084-8.
69. [69] Andersen KB. The fate of the surface protein gp70 during entry of retrovirus into mouse fibroblasts. Virology 1985;142:112-20.
70. [70] Andersen KB. Cleavage fragments of the retrovirus surface proteins gp70 during virus entry. J Gen Virol 1987;68:2193-202.
71. [71] Andersen KB, Skov H. Retrovirus-induced cell fusion is enhanced by protease treatment. J Gen Virol 1989;70:1921-7.
72. [72] Vogt PK. Phenotypic mixing in the avian tumor virus group. Virology 1967;32:708-15.
73. [73] Mastromarino P, Conti C, Goldoni P, Hautte-Coeur B, Orsi N. Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachement and fusion at acidic pH. J Gen Virol 1987;68:2359-69.
74. [74] Schlegel R, Tralka T, Willinghan M, Pastan I. Inhibition of VSV binding and infectivity by phosphotidylserine: is phosphatidylserine a VSV-binding site? Cell 1983;32:639-46.
75. [75] Yee J, Miyanohara A, Laporte P, Bouic K, Burns J, Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994;91:9564-8.
76. [76] Sharma S, Cantwell M, Kipps TJ, Friedmann T. Efficient infection of a human T-cell line and of human primary peripheral blood leucocytes with a pseudotyped retrovirus vector. Proc Natl Acad Sci USA 1996;93:11842-7.
77. 2- cells. Exp Hematol 1996;24:738-47.
78. + hematopoietic progenitors. Gene Ther 1997;4:918-27.
79. [79] Burns J, Fridmann T, Driever W, Burrascano M, Yee J. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993;90:8033-7.
80. [80] Yang Y, Vanin E, Whitt M, et al. Inducible, high-level production of infectious Murine Leukemia Retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum Gene Ther 1995;6:1203-13.
81. [81] Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-7.
82. [82] Naldini L, Blomer U, Gage FH, Trono D. Efficient transfer, integration and sustained long-term expression of the transgene in adult rat braisns injected with a lentiviral vector. Proc Natl Acad Sci USA 1996;93:11382-8.
83. [83] Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15:871-5.
84. [84] Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997;94:10319-23.
85. [85] Corbeau P, Kraus G, Wong-Staal F. Efficient gene transfer by human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci USA 1996;93:14070-5.
86. [86] Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc Natl Acad Sci USA 1996;93:15266-71.
87. + cells with a human immunodeficiency virus type 1-based stomatitis virus envelope glycoprotein G. J Virol 1996;70:2581-5.
88. + cells. J Virol 1996;71:3341-5.
89. [89] Schnierle BS, Stitz J, Bosch V, et al. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells. Proc Natl Acad Sci USA 1997;94:8640-5.
90. [90] Roux P, Jeanteur P, Piechaczyk M. A versatile and potentially general approach to the targeting of specific cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses. Proc Natl Acad Sci USA 1989;86:9079-83.
91. [91] Legrain P, Goud B, Butin G. Increase retroviral infection in vitro by the binding of antiretroviral antibodies. J Virol 1986;60:1141-4.
92. [92] Etienne-Julan M, Roux P, Carillo S, Jeanteur P, Piechaczyk M. The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J Gen Virol 1992;73:3251-5.
93. [93] Goud B, Legrain P, Butin G. Antibody-mediated binding of a murine ecotropic Moloney retroviral vector to human cells allow internalization but not the establisment of the proviral state. Virology 1988;163:251-4.
94. [94] Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins ML, Russell SJ. Retroviral targeting by envelopes expressing an N-terminal binding domain. J Virol 1995;69:6314-22.
95. [95] Neda H, Wu C, Wu G. Chemical modification of an ecotropic murine leukemia virus results in redirection of its target cell specificity. J Biol Chem 1991;266:14143-6.
96. [96] Kasahara N, Dozy A, Kan Y. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994;266:1373-6.
97. [97] Han X, Kasahara N, Kan YW. Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 1995;92:9747-51.
98. [98] Matano T, Odawara T, Iwamoto A, Yoshikura H. Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J Gen Virol 1995;76:3165-9.
99. [99] Russell S, Hawkins R, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acid Res 1993;21:1081-5.
100. [100] Chu T-HT, Martinez I, Sheay W, Dornburg R. Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. Gene Ther 1994;1:292-9.
101. [101] Chu T-H, Dornburg R. Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol 1995;69:2659-63.
102. [102] Chu T-H, Dornburg R. Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol 1997;71:720-5.
103. [103] Somia N, ZoppE M, Verma I. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995;92:7570-4.
104. [104] Marin M, Noël D, Valsesia-Wittman S, et al. targeted infection of human cells via major histocompatibility complex class I molecules by moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J Virol 1996;70:2957-62.
105. [105] Ager S, Nilson BHK, Morling FJ, Peng KW, Cosset FL, Russell S. Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. Hum Gene Ther 1996;7:2157-64.
106. [106] Valsesia-Wittmann S, Morling FJ, Hatziioannou T, Russell SJ, Cosset FL. Receptor co-operation in retrovirus entry: recruitment of an auxiliary mechanism after retargeted binding. EMBO J 1997;16:1214-23.
107. [107] Schnierle B, Groner B. Retroviral targeted delivery. Gene Ther 1996;3:1069-73.
108. [108] Schnierle B, Moritz D, Jeschke M, Groner B. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. Gene Ther 1996;3:334-42.
109. [109] Nilson B, Morling F, Cosset F-L, Russell S. Targeting of retroviral vectors through protease-substrate interactions. Gene Ther 1996;3:280-6.
110. [110] Valsesia-Wittmann S, Drynda A, Deleage G, et al. Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 1994;68:4609-19.
111. [111] Pass D, Davey RA, Hamson CA, Kim PS, Cunningham JM, Berger JM. Structure of a murine leukemia virus receptor-binding glycoprotein at 2.0 Å resolution. Science 1997;277:1662-6.
112. [112] Arthur L, Bess J, Sowder R, Benveniste R, Mann D, Chermann J-C, Henderson L. Cellular proteins bound to immunodeficiency virus: implications for pathogenesis and vaccines. Science 1992;258:1935-8.
113. [113] Young J, Bates P, Willert K, Varmus H. Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science 1990;250:1421-3.
114. [114] Wang H, Paul R, Burgeson RE, Keene DR, Kabat D. Plasma membrane receptors for ecotropic murine retroviruses require a limiting accessory factor. J Virol 1991;65:6468-77.
115. [115] Ohno K, Sawai K, Iijima Y, Levin B, Meruelo D. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 1997;15:763-7.
116. [116] Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecifc antibodies. J Virol 1996;70:6831-8.
117. [117] Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996;14:1574-8.
118. [118] Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE. The adenobody approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther 1997;4:1004-12.
119. [119] Mebatsion T, Finke S, Weiland F, Conzelmann KK. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997;90:841-7.
120. [120] Schnell MJ, Johnson JE, Buonocore L, Rose JK. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997;90:849-57.
121. [121] Tabin CJ, Hoffmann JW, Goff SP, et al. Adaptation of a retrovirus as a eucaryotic vector transmitting the herpes simplex virus thymidine kinase gene. Mol Cell Biol 1982;2:426-36.
122. [122] Watanabe S, Temin HM. Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5′ long terminal repeat and the start of the gag gene. Proc Natl Acad Sci USA. 1982;79:5986-90.
123. [123] Sorge J, Hughes SH. Splicing of intervening sequences introduced into an infectious retroviral vector. J Mol Appl Genet 1982;1:547-59.
124. [124] Levy JP, Muldoon RR, Zolotukin S, et al. Retroviral transfer and expression of humanized, red shifted green fluorescent protein into human tumor cells. Nat Biotechnol 1996;14:610-4.
125. [125] Klein D, Indraccolo S, von Rombs K, et al. Rapid identification of viable retrovirus transduced cells using the green fluorescent protein as a marker. Gene Ther 1997;4:1256-60.
126. [126] Levine F, Yee JK, Friedmann T. Efficient gene expression in mammalian cells from a dicistronic transcriptional unit in an improved retro viral vector. Gene 1991;108:167-74.
127. [127] Koo HM, Brown AMC, Kaufman RJ, et al. A spleen necrosis virus-based retroviral vector which expresses two genes from a dicistronic mRNA. Virology 1992;186:669-75.
128. [128] Xu L, Yee JK, Wolff JA, et al. Factors affecting long-term stability of Moloney murine leukemia virus-based vectors. Virology 1989;171:331-41.
129. [129] Li M, Hantzopoulos PA, Banerjee SC, et al. Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. Hum Gene Ther 1992;3:381-90.
130. [130] McLachlin JR, Mittereder N, Daucher MB, et al. Factors affecting retroviral vector function and structural integrity. Virology 1993;195:1-5.
131. [131] Wadhwa R, Smith-Pereira OM, Reddel RR, et al. Correlation between complementation group for immortality and the cellular distributon of mortalin. Exp Cell Res 1995;216:101-6.
132. [132] Lund AH, Duch M, Pedersen FS. Transcriptional silencing of retroviral vectors. J Biomed Sci 1996;3:365-78.
133. [133] Richards CA, Huber BE. Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum Gene Ther 1993;4:143-50.
134. [134] Vernet M, Cebrian J. cis-Acting elements that mediate the negative regulation of Moloney murine leukemia virus in mouse early embryos. J Virol 1996;70:5630-3.
135. [135] Beck-Engeser G, Stocking C, Just U, et al. Retroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and precursor cell lines, but retroviral infection is reduced in more primitive cells. Hum Gene Ther 1991;2:61-70.
136. [136] Baum C, Hegewischbecker S, Eckert HG, et al. Novel retroviral vectors for efficient expression of the multidrug-resistance (MDR-1) gene in early hematopoietic-cells. J Virol 1995;69:7541-7.
137. [137] Challita PM, Skelton D, El-Khoueiry A, et al. Multiple modification in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol 1995;69:748-55.
138. [138] Robbins PB, Yu X-J, Skelton DM, et al. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J Virol 1997;71:9466-74.
139. [139] Gunzburg WH, Hynes NE, Groner B. The methylation pattern of endogenous mouse mammary tumor virus proviral genes is tissue specific and stably inherited. Virology 1984;138:212-24.
140. [140] Jaenisch R, Schnieke A, Harbers K. Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues. Proc Natl Acad Sci USA 1985;82:1451-5.
141. [141] Gunzburg WH, Groner B. The chromosomal integration site determines the tissue-specific methylation of mouse mammary tumour virus proviral genes. EMBO J 1984;3:1129-35.
142. [142] Lynch CM, Israel DI, Kaufmann RJ, et al. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993;4:259-72.
143. [143] Duch M, Paludan K, Jorgensen P, et al. Lack of correlation between basal expression levels and susceptibility to transcriptional shutdown among single-gene murine leukemia virus vector proviruses. J Virol 1994;68:5596-601.
144. [144] Gunzburg WH, Salmons B, Zimmermann B, et al. A mammary-specific promoter directs expression of growth hormone not only to the mammary gland, but also to Bergman glia cells in transgenic mice. Mol Endocinol 1991;5:123-33.
145. [145] Dillon N, Grosveld F. Transcriptional regulation of multigene loci: multilevel control. Trends Genet 1993;9:134-7.
146. [146] Chang JC, Liu D, Kan YW. A 36-bp core sequence of locus control region enhances retrovirally tranferred human β-globin gene expression. Proc Natl Acad Sci USA 1992;89:3107-10.
147. [147] Sadelain M, Wang CHJ, Antoniou M, et al. Generation of a high-titer retroviral vector capable of expressing high levels of the human β-globin gene. Proc Natl Acad Sci USA 1995;92:6728-32.
148. [148] Ellis J, Pasceri P, Tan-Un KC, et al. Evaluation of β-globin gene therapy constructs in single copy transgenic mice. Nucleic Acid Res 1997;25:1296-302.
149. [149] Gerasimova TI, Corces VG. Boundary and insulator elements in chromosomes. Curr Opin Genet Dev 1996;6:185-92.
150. [150] Felsenfeld G, Boyes J, Chung J, et al. Chromatin structure and gene expression. Proc Natl Acad Sci USA 1996;93:9384-8.
151. [151] Geyer PK. The role of insulator elements in defining domains of gene expression. Curr Opin Genet Dev 1997;7:242-8.
152. [152] Majors J. The structure and function of retroviral long terminal repeats. Curr Top Microbiol Immunol 1990;157:49-92.
153. [153] Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984;39:459-67.
154. [154] Emerman M, Temin HM. Comparison of promoter suppression in avian and murine retrovirus vectors. Nucleic Acid Res 1986;14:9381-96.
155. [155] Jolly DJ, Willis RC, Friedmann T. Variable stability of a selectable provirus after retroviral vector gene transfer into human cells. Mol Cell Biol 1986;6:1141-7.
156. [156] Belmont J, MacGregor G, Wager-Smith K, et al. Expression of human adenosine deaminase in murine hematopoietic cells. Mol Cell Biol 1988;8:5116-25.
157. [157] McIvor R, Johnson M, Miller A, et al. Human purine nucleoside phosphorylase and adenosine deaminase: gene transfer into cultured cells and murine hematopoietic stem cells by using recombinant amphotropic retroviruses. Mol Cell Biol 1987;7:838-46.
158. [158] Hoeben RC, Migchielsen AAJ, van der Jagt RCM, et al. Inactivation of the moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol 1991;65:904-12.
159. [159] Wu X, Holschen J, Kennedy SC, et al. Retroviral vector sequences may interact with some internal promoters and influence expression. Hum Gene Ther 1996;7:159-71.
160. [160] Mavilio F, Ferrari G, Rossini S, et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994;83:1988-97.
161. [161] Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995;92:6733-7.
162. [162] McGrane M, de Vente J, Yun J, et al. Tissue-specific expression and dietary regulation of a chimeric phosphoenolpyruvate carboxykinase/bovine growth hormone gene in transgenic mice. J Biol Chem 1988;263:11443-51.
163. [163] Hatzoglou M, Lamers W, Bosch F, et al. Hepatic gene transfer in animals using retroviruses containing the promoter from the gene for phosphoenolpyruvate carboxykinase. J Biol Chem 1990;265:17285-93.
164. [164] Hafenrichter DG, Wu XY, Rettinger SD, et al. Quantitative evaluation of liver specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood 1994;84:3394-404.
165. [165] Huber BE, Richards CA, Krenitsky TA. Retro viral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci USA. 1991;88:8039-43.
166. [166] Rettinger SD, Kennedy SC, Wu X, et al. Liver-directed gene therapy: quantitative evaluation of promoter elements by using in vivo retroviral transduction. Proc Natl Acad Sci USA 1994;91:1460-4.
167. [167] Wu H, Wade M, Krall L, et al. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development, and regeneration. Gene Dev 1996;10:245-60.
168. [168] Vile RG, Nelson JA, Castleden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994;54:6228-34.
169. [169] Vile RG, Diaz RM, Miller N, et al. Tissue-specific gene-expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer promoter. Virology 1995;214:307-13.
170. [170] Harris JD, Gutierrez AA, Hurst HC, et al. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994;1:170-5.
171. [171] Arteaga CL, Holt JT. Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. Cancer Res 1996;56:1098-103.
172. [172] Gazit G, Kane SE, Nichols P, et al. Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res 1995;55:1660-3.
173. [173] Apperley JF, Luskey BD, Williams DA. Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long-term expression. Blood 1991;78:317-9.
174. [174] Artelt P, Grannemann R, Stocking C, et al. The prokaryotic neomycin-resistance-encoding gene acts as a transcriptional silencer in eukaryotic cells. Gene 1991;99:249-54.
175. [175] Yu SF, von Ruden T, Kantoff PW, et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986;83:3194-8.
176. [176] Soriano P, Friedrich G, Lawinger P. Promoter interactions in retrovirus vectors introduced into fibroblasts and embryonic stem cells. J Virol 1991;65:2314-9.
177. [177] Hantzopoulos PA, Sullenger BA, Ungers G, et al. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci USA 1989;86:3519-23.
178. [178] Adam MA, Osbourne WRA, Miller AD. R-region cDNA inserts in retroviral vectors are compatible with virus replication and high level protein synthesis from the insert. Hum Gene Ther 1995;6:1169-76.
179. [179] Valerie D, Einerhand MP, Wamsley PM, et al. Retrovirus-mediated gene transfer into embryonal carcinoma and hemopoietic stem cells: expression from a hybrid long terminal repeat. Gene 1989;84:419-27.
180. [180] van den Wollenberg DJ, Hoeben RC, van Ormondt H, et al. Insertion of the human cytomegalovirus enhancer into a myeloproliferative sarcoma virus long terminal repeat creates a high-expression retroviral vector. Gene 1994;144:237-41.
181. [181] Robinson D, Elliott JF, Chang LJ. Retroviral vector with a CMV-IE/HIV-TAR hybrid LTR gives high basal expression levels and is up-regulated by HIV-1 Tat. Gene Ther 1995;2:269-78.
182. [182] Ferrari G, Salvatori G, Rossi C, et al. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther 1995;6:733-42.
183. [183] Moore K, Scarpa M, Kooyer S, et al. Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector. Hum Gene Ther 1991;2:307-15.
184. [184] Chen H, Yoshimura FK. Identification of a region of a murine leukemia virus long terminal repeat with novel transcriptional regulatory activities. J Virol 1994;68:3308-16.
185. [185] Gunzburg WH, Sailer R, Salmons B. Retroviral vectors directed to predefined cell types for gene therapy. Biologicals 1995;23:5-12.
186. [186] Salmons B, Saller RM, Baumann J, et al. Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia 1995;9 (Suppl 1):53-60.
187. [187] Mrochen S, Klein D, Salmons B, et al. Inducible expression of p21WAF-1/CIP-1/SDI-1 from a promoter-conversion retroviral vector. J Mol Med 1997;75:820-8.
188. [188] Gunzburg WH, Karle P, Mrochen S, et al. Regulated gene expression after retroviral vector mediated delivery of cancer relevant therapeutic genes. Recent Res Cancer Res 1997;144:116-26.
189. [189] Saller RM, Özturk F, Salmons B, et al. Construction and characterization of a hybrid mouse mammary tumor virus/murine leukemia virus, based retroviral vector. J Virol 1998;72:1699-703.
190. [190] Saller RM. Design von locus- und gewebespezifische retroviralen Vektoren für eine in vivo Gentherapie. Doctoral Thesis, Biology Faculty, Ludwig-Maximilian Universität, Munich, 1994.
191. [191] Fleuchaus AG. Modellsystem zur gentherapeutischen Behandlung von Erkrankungen des Pankreas mit retroviralen Vektoren. Diploma Thesis, Ludwig-Maximilian Universität, Munich, 1995.
192. [192] Gunzburg WH, Fleuchaus A, Saller RM, et al. Retroviral vector targeting for gene therapy. Cytokines Mol Ther 1996;2:177-84.
193. [193] Gunzburg WH, Salmons B. Factors controlling the expression of mouse mammary tumour virus. Biochem J 1992;283:625-32.
194. [194] Sparmann G, Walther W, Günzburg WH, et al. Conditional expression of human TNF-α: a system for inducible cytotoxicity. Int J Cancer 1994;59:103-7.
195. [195] Cannon PM, Kim N, Kingsman SM, et al. Murine leukemia virus-based Tat-inducible long terminal repeat replacement vectors: a new system for anti-human immunodeficiency virus gene therapy. J Virol 1996;70:8234-40.
196. [196] Luznik L, Kraus G, Guatelli J, et al. Tat-independent replication of human immunodeficiency viruses. J Clin Invest 1995;95:328-32.
197. [197] Walther W, Wendt J, Stein U. Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy. Gene Ther 1997;4:544-52.
198. [198] Paulus W, Baur I, Boyce FM, et al. Self-contained, tetracyclin-regulated retroviral vector system for gene delivery to mammalian cells. J Virol 1996;70:62-7.
199. [199] Hwang J-J, Scuric Z, Anderson WF. Novel retroviral vector transferring a suicide gene and a selectable marker gene with enhanced gene expression by using a tetracycline-responsive expression system. J Virol 1996;70:8138-41.
200. [200] Watsuji T, Okamoto Y, Emi N, et al. Controlled gene expression with a reverse tetracycline-regulated retroviral vector (RTRV) system. Biochem Biophys Res Commun 1997;234:769-73.
201. [201] Bohl D, Naffakh N, Heard J. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 1997;3:299-305.
202. [202] Wang S, Beattie GM, Hayek A, et al. Development of a VSV-G protein pseudotyped retroviral vector system expressing dominant oncogenes from a lacO-modified inducible LTR promoter. Gene 1996;182:145-50.
203. [203] Chang BD, Roninson IB. Inducible retroviral vectors regulated by lac repressor in mammalian cells. Gene 1996;183:137-42.